Analyst Ratings For Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Today, Piper Jaffray Companies reiterated its Hold rating on Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a price target of $2.00.
There are 5 hold ratings on the stock.
The current consensus rating on Arrowhead Pharmaceuticals (NASDAQ:ARWR) is Hold (Score: 2.00) with a consensus target price of $1.80 per share, a potential 0.56% upside.
Some recent analyst ratings include
- 7/28/2017-Piper Jaffray Companies Reiterated Rating of Hold.
- 4/12/2017-Jefferies Group LLC Reiterated Rating of Hold.
- 11/30/2016-William Blair was Downgraded by analysts at William Blair from a “Outperform ” rating to a ” Market Perform” rating. They now have a $2.00 price target on the stock, up previously from $12.00 .
- 11/30/2016-Cantor Fitzgerald was Downgraded by analysts at Cantor Fitzgerald from a “Buy ” rating to a ” Hold” rating. They now have a $1.00 price target on the stock, up previously from $15.00 .
- 11/30/2016-Chardan Capital was Downgraded by analysts at Chardan Capital from a “Buy ” rating to a ” Neutral” rating. They now have a $2.00 price target on the stock, up previously from $8.00 .
- 8/5/2015-Royal Bank Of Canada Reiterated Rating of Hold.
Recent Insider Trading Activity For Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Arrowhead Pharmaceuticals (NASDAQ:ARWR) has insider ownership of 4.57% and institutional ownership of 32.75%.
- On 10/14/2016 Douglas B. Given, Director, sold 12,000 with an average share price of $6.72 per share and the total transaction amounting to $80,640.00. View SEC Filing
- On 8/23/2016 Kenneth Allen Myszkowski, CFO, sold 6,900 with an average share price of $8.00 per share and the total transaction amounting to $55,200.00. View SEC Filing
- On 8/22/2016 Kenneth Allen Myszkowski, CFO, sold 13,100 with an average share price of $8.00 per share and the total transaction amounting to $104,800.00. View SEC Filing
- On 12/30/2015 Kenneth Allen Myszkowski, CFO, sold 23,347 with an average share price of $6.13 per share and the total transaction amounting to $143,117.11. View SEC Filing
- On 10/28/2015 Mauro Ferrari, Director, bought 400 with an average share price of $7.62 per share and the total transaction amounting to $3,048.00. View SEC Filing
- On 10/9/2015 Mauro Ferrari, Director, bought 1,900 with an average share price of $6.19 per share and the total transaction amounting to $11,761.00. View SEC Filing
- On 1/5/2015 David L Lewis, Insider, sold 15,000 with an average share price of $8.01 per share and the total transaction amounting to $120,150.00. View SEC Filing
Recent Trading Activity for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Shares of Arrowhead Pharmaceuticals closed the previous trading session at 1.79 down -0.06 -3.24% with 986,852 shares trading hands.
